Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.
Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.